Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:AEZS
- CUSIP: N/A
- Web: www.aezsinc.com
Capitalization:- Market Cap: $32.97 million
- Outstanding Shares: 14,333,000
Average Prices:- 50 Day Moving Avg: $1.19
- 200 Day Moving Avg: $2.14
- 52 Week Range: $0.78 - $5.59
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.26
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $930,000.00
- Price / Sales: 35.45
- Book Value: $0.39 per share
- Price / Book: 5.90
Profitability:- EBIDTA: ($27,830,000.00)
- Net Margins: -2,732.69%
- Return on Equity: -425.52%
- Return on Assets: -79.10%
Debt:- Current Ratio: 5.61%
- Quick Ratio: 5.61%
Misc:- Average Volume: 2.17 million shs.
- Beta: 1.1
- Short Ratio: 0.26
Frequently Asked Questions for AEterna Zentaris (NASDAQ:AEZS)
What is AEterna Zentaris' stock symbol?
AEterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."
How were AEterna Zentaris' earnings last quarter?
AEterna Zentaris Inc. (NASDAQ:AEZS) announced its quarterly earnings data on Monday, May, 8th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.33) by $0.02. The firm earned $0.26 million during the quarter, compared to analysts' expectations of $0.85 million. AEterna Zentaris had a negative net margin of 2,732.69% and a negative return on equity of 425.52%. The company's revenue for the quarter was up 8.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.37) earnings per share. View AEterna Zentaris' Earnings History.
Where is AEterna Zentaris' stock going? Where will AEterna Zentaris' stock price be in 2017?
3 analysts have issued twelve-month price targets for AEterna Zentaris' shares. Their predictions range from $3.00 to $6.00. On average, they anticipate AEterna Zentaris' stock price to reach $4.33 in the next year. View Analyst Ratings for AEterna Zentaris.
What are analysts saying about AEterna Zentaris stock?
Here are some recent quotes from research analysts about AEterna Zentaris stock:
- 1. According to Zacks Investment Research, "AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. " (7/11/2017)
- 2. Maxim Group analysts commented, "Summary Aeterna Zentaris announced its plan to file a new drug application (NDA) for Macrilen (macimorelin) for adults growth hormone deficiency (AGHD) in 3Q17, following its meeting with the FDA on March 29, 2017." (3/30/2017)
Who are some of AEterna Zentaris' key competitors?
Some companies that are related to AEterna Zentaris include NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), CASI Pharmaceuticals (CASI), Regulus Therapeutics (RGLS), BioLineRx (BLRX), Sunesis Pharmaceuticals (SNSS), ReNeuron Group Plc (RENE), OvaScience (OVAS), Fibrocell Science (FCSC), Senomyx (SNMX), Bio-Path Holdings (BPTH), Prima BioMed Ltd (PBMD), Threshold Pharmaceuticals (THLD), Aptose Biosciences (APTO), Burcon NutraScience Corp (BUR), Cleveland BioLabs (CBLI), Scancell Holdings Plc (SCLP) and Nabriva Therapeutics PLC - (NBRV).
Who are AEterna Zentaris' key executives?
AEterna Zentaris' management team includes the folowing people:
- David A. Dodd, Chairman of the Board, President, Chief Executive Officer
- Dennis Turpin CA, Chief Financial Officer, Senior Vice President
- Philip Allen Theodore, Senior Vice President, Chief Administrative Officer, General Counsel
- Richard Sachse M.D. Ph.D., Senior Vice President, Chief Scientific Officer, Chief Medical Officer
- Jude Dinges, Chief Commercial Officer, Senior Vice President
- Genevieve Lemaire, Chief Accounting Officer, Vice President - Finance
- Michael Teifel, Vice President - Non-Clinical Sciences
- Juergen H. L. Ernst, Lead Independent Director
- Michael A. Cardiff, Director
- Kenneth E. Newport CPA, Director
How do I buy AEterna Zentaris stock?
Shares of AEterna Zentaris can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AEterna Zentaris' stock price today?
One share of AEterna Zentaris stock can currently be purchased for approximately $2.30.
MarketBeat Community Rating for AEterna Zentaris (NASDAQ AEZS)MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for AEterna Zentaris (NASDAQ:AEZS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $4.33 (88.41% upside) |
Analysts' Ratings History for AEterna Zentaris (NASDAQ:AEZS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/19/2017 | Maxim Group | Boost Price Target | Buy -> Buy | $2.00 -> $4.00 | High |  |
| 7/5/2017 | HC Wainwright | Set Price Target | Buy | $3.00 | High | |
| 1/8/2017 | Canaccord Genuity | Set Price Target | Buy | $7.50 -> $6.00 | N/A | |
(Data available from 7/24/2015 forward)
Earnings History for AEterna Zentaris (NASDAQ:AEZS)Earnings History by Quarter for AEterna Zentaris (NASDAQ AEZS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/8/2017 | 3/31/2017 | ($0.33) | ($0.31) | $0.85 million | $0.26 million | View | Listen | |
| 3/15/2017 | 12/31/2016 | ($0.73) | ($0.71) | $0.40 million | $0.30 million | View | N/A | |
| 11/8/2016 | Q316 | ($0.74) | ($0.61) | $0.22 million | $0.27 million | View | Listen | |
| 5/9/2016 | Q216 | ($0.82) | ($0.71) | $0.50 million | $0.24 million | View | N/A | |
| 3/29/2016 | Q415 | ($1.30) | ($1.46) | $0.25 million | $0.10 million | View | N/A | |
| 11/5/2015 | Q315 | ($0.06) | ($0.07) | $0.20 million | $0.17 million | View | N/A | |
| 8/13/2015 | Q215 | ($0.08) | ($0.14) | $0.55 million | $0.20 million | View | Listen | |
| 5/7/2015 | Q1 2015 | ($0.10) | ($0.13) | | $0.07 million | View | N/A | |
| 3/17/2015 | Q414 | ($0.16) | $0.06 | | $0.01 million | View | N/A | |
| 3/20/2014 | Q413 | ($0.04) | ($0.22) | $12.41 million | | View | N/A | |
| 3/21/2013 | Q412 | ($0.31) | ($0.29) | $7.96 million | $9.16 million | View | N/A | |
| 11/13/2012 | Q312 | ($0.43) | ($0.35) | $8.38 million | $7.10 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for AEterna Zentaris (NASDAQ:AEZS)Current Year EPS Consensus Estimate: $-1.36 EPS
Next Year EPS Consensus Estimate: $-0.54 EPS
Dividend History for AEterna Zentaris (NASDAQ:AEZS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for AEterna Zentaris (NASDAQ:AEZS)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for AEterna Zentaris (NASDAQ:AEZS)
Latest Headlines for AEterna Zentaris (NASDAQ:AEZS)
| Source: |
|
| Date | Headline |
|---|
 | AEterna Zentaris Inc. (USA) (AEZS) CEO’s Departure Raises Questions
finance.yahoo.com - July 24 at 1:43 PM |
 | Aeterna Zentaris Forms Strategic Review Committee, Appoints Michael Ward As CEO
www.nasdaq.com - July 21 at 2:03 AM |
 | After-Hours Stock Movers 07/20: (AEZS) (ATHN) (MSFT) Higher; (MANH) (NCR) (MXIM) Lower (more...)
www.streetinsider.com - July 20 at 9:03 PM |
| Aeterna Zentaris Forms Strategic Review Committee and Appoints Michael Ward as CEO
finance.yahoo.com - July 20 at 9:02 PM |
| BUZZ-US STOCKS ON THE MOVE- Sears, Sarepta Qualcomm, A Schulman - Nasdaq
www.nasdaq.com - July 20 at 4:01 PM |
| Today's Research Reports on Stocks to Watch: Vertex Pharmaceuticals and Aeterna Zentaris
finance.yahoo.com - July 20 at 4:01 PM |
 | Gainers & Losers Of July 19: AEZS, VRTX, AGRX, PTI, INO...
www.finanznachrichten.de - July 20 at 2:39 AM |
 | Drug Company More than Doubles in Price on FDA Notification
www.baystreet.ca - July 19 at 4:36 PM |
 | Mid-Afternoon Market Update: Scripps Rises On Report Of Merger Talks With Discovery; DryShips Shares Slide - Benzinga
www.benzinga.com - July 19 at 4:26 PM |
 | AEterna Zentaris's stock more than doubles on heavy volume after favorable FDA ruling - MarketWatch
www.marketwatch.com - July 19 at 4:26 PM |
| AEterna Zentaris's stock more than doubles on heavy volume after favorable FDA ruling
finance.yahoo.com - July 19 at 4:26 PM |
 | AEterna Zentaris Inc. (NASDAQ:AEZS) Price Target Raised to $4.00
www.americanbankingnews.com - July 19 at 1:56 PM |
 | FDA Nod For GILD, It's Take 2 For AEZS' Macrilen, VRTX Soars On CF Drug Trials
www.rttnews.com - July 19 at 2:29 AM |
| After-Hours Stock Movers 07/18: (AEZS) (VRTX) (EXPO) Higher; (DRYS) (HDP) (IBM) (CSX) (UAL) Lower (more...) - StreetInsider.com
www.streetinsider.com - July 18 at 9:28 PM |
| Aeterna Zentaris (AEZS) Granted 12/30/17 PDUFA Date for Macrilen NDA Approval - StreetInsider.com
www.streetinsider.com - July 18 at 9:28 PM |
| NDA for Macrilen™ for the Evaluation of Growth Hormone Deficiency in Adults Granted December 30, 2017 PDUFA Date
finance.yahoo.com - July 18 at 9:28 PM |
| AEterna Zentaris Inc. (AEZS) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - July 11 at 6:02 PM |
| Brokerages Expect AEterna Zentaris Inc. (AEZS) to Post ($0.41) EPS
www.americanbankingnews.com - July 10 at 2:30 PM |
| AEterna Zentaris Inc. (AEZS) PT Set at $3.00 by HC Wainwright
www.americanbankingnews.com - July 9 at 6:02 PM |
 | Do Options Traders Know Something About Aeterna Zentaris (AEZS) Stock We Don't?
www.zacks.com - July 8 at 8:33 PM |
| Do Options Traders Know Something About Aeterna Zentaris (AEZS) Stock We Don't? - Nasdaq
www.nasdaq.com - July 7 at 5:23 PM |
| Do Options Traders Know Something About Aeterna Zentaris (AEZS) Stock We Don't?
finance.yahoo.com - July 7 at 5:23 PM |
| Maxim Group Analysts Give AEterna Zentaris Inc. (AEZS) a $2.00 Price Target
www.americanbankingnews.com - July 3 at 6:25 PM |
| Aeterna Zentaris (AEZS) Resubmits NDA for Macrilen for Evaluation of AGHD
www.streetinsider.com - June 30 at 8:41 PM |
| Aeterna Zentaris (AEZS) Resubmits NDA for Macrilen for Evaluation ... - StreetInsider.com
www.streetinsider.com - June 30 at 3:39 PM |
| Aeterna Zentaris Resubmits NDA for Macrilen™ for the Evaluation of Growth Hormone Deficiency in Adults
finance.yahoo.com - June 30 at 3:38 PM |
| Zacks: AEterna Zentaris Inc. (AEZS) Given $2.50 Consensus Target Price by Brokerages
www.americanbankingnews.com - June 23 at 8:40 AM |
| Implied Volatility Surging for Aeterna Zentaris (AEZS) Stock Options
finance.yahoo.com - June 16 at 3:48 PM |
 | Aeterna Zentaris to Present at 2017 Marcum MicroCap Conference ... - Business Wire (press release)
www.businesswire.com - June 9 at 3:28 PM |
| Aeterna Zentaris to Present at 2017 Marcum MicroCap Conference
finance.yahoo.com - June 9 at 3:28 PM |
| AEterna Zentaris Inc. (AEZS) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - June 8 at 8:14 AM |
| Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 4:21 PM |
| Today's Research Reports on Stocks to Watch: AEterna Zentaris and Dynavax Technologies
finance.yahoo.com - May 30 at 11:05 AM |
| AEterna Zentaris Inc. (AEZS) Receives Consensus Recommendation of "" from Analysts
www.americanbankingnews.com - May 24 at 2:34 PM |
| Is the Options Market Predicting a Spike in Aeterna Zentaris (AEZS) Stock? - Nasdaq
www.nasdaq.com - May 22 at 3:22 PM |
| Is the Options Market Predicting a Spike in Aeterna Zentaris (AEZS) Stock?
finance.yahoo.com - May 22 at 3:22 PM |
| AEterna Zentaris Inc. (AEZS) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - May 12 at 4:40 PM |
| AEterna Zentaris Inc. (AEZS) Price Target Cut to $3.00 by Analysts at HC Wainwright
www.americanbankingnews.com - May 10 at 7:56 AM |
| Aeterna Zentaris Announces Election of Directors at 2017 Shareholders' Meeting
finance.yahoo.com - May 9 at 8:23 PM |
| AEterna Zentaris Inc. (AEZS) Announces Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - May 9 at 1:38 PM |
| Aeterna Zentaris Reports First Quarter 2017 Financial and Operating Results
finance.yahoo.com - May 8 at 8:21 PM |
 | AEterna Zentaris: Learning From Mistakes - Seeking Alpha
seekingalpha.com - May 5 at 3:23 PM |
| AEterna Zentaris Inc. (AEZS) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - May 5 at 9:46 AM |
| AEterna Zentaris (AEZS) Given News Sentiment Rating of 0.22
www.americanbankingnews.com - May 3 at 10:15 AM |
| Today's Research Reports on Stocks to Watch: AEterna Zentaris and Exelixis
finance.yahoo.com - May 2 at 3:25 PM |
| Aeterna Zentaris to Announce First Quarter 2017 Financial and Operating Results on May 8, 2017
finance.yahoo.com - May 2 at 3:25 PM |
 | IIROC Trading Halt - AEZS
www.bizjournals.com - May 1 at 3:21 PM |
| Aeterna Zentaris (AEZS) Phase 3 Study of Zoptrex Doesn't Achieve Primary Endpoint
www.streetinsider.com - May 1 at 3:21 PM |
| Pre-Open Movers 05/01: (OCN) (XXII) (TWTR) Higher; (FNBC) (AEZS) (ITCI) Lower (more...) - StreetInsider.com
www.streetinsider.com - May 1 at 9:54 AM |
| BUZZ-U.S. STOCKS ON THE MOVE-First NBC Bank, Twitter, Tribune Media, Aeterna Zentaris, Neurotrope - Nasdaq
www.nasdaq.com - May 1 at 9:54 AM |
AEterna Zentaris (AEZS) Chart for Monday, July, 24, 2017
